Sarepta Presents Preclinical SRP-1003 Data in DM1
Sarepta said it presented preclinical data on SRP-1003 at the Oligonucleotide Therapeutics Society annual meeting, reporting robust knockdown of pathogenic DMPK RNA in the nucleus.
Sarepta said it presented preclinical data on SRP-1003 at the Oligonucleotide Therapeutics Society annual meeting, reporting robust knockdown of pathogenic DMPK RNA in the nucleus.